Nicola Di Renzo
0000-0003-0604-6934
Publication & Citation Trends
Publications
0 total
Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study
Cited by 0
Semantic Scholar
Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate‐1‐Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI)
Cited by 0
Semantic Scholar
Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study
Cited by 0
Semantic Scholar
Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort
Cited by 0
Semantic Scholar
Clinical impact of immunoglobulin heavy chain repertoire in mantle cell lymphoma: A study from the Fondazione Italiana Linfomi (FIL) Phase III MCL0208 trial
Cited by 0
Semantic Scholar
Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care?
Cited by 1
Semantic Scholar
Integrated clinical and radiomic PET-FLIPI score for risk stratification in newly diagnosed follicular lymphoma
Cited by 0
Semantic Scholar
JAK2 46/1 (GGCC) Haplotype in Oncogenesis, as Risk Stratifier, and Indicator for Drug Resistance in Myeloproliferative Neoplasms
Cited by 1
Semantic Scholar
Research Topics
Chronic Lymphocytic Leukemia Research
(111)
Lymphoma Diagnosis and Treatment
(100)
Multiple Myeloma Research and Treatments
(53)
Acute Myeloid Leukemia Research
(42)
Chronic Myeloid Leukemia Treatments
(39)
Affiliations
University of Verona
Universität Hamburg
Mario Negri Institute for Pharmacological Research
University of Pavia
Casa Sollievo della Sofferenza